Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $650
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target from $600 to $650.
Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target from $600 to $650.